Begin with the Exit in Mind

Fund Details

The General Partner of Epic BioVentures I is Epic BioVentures, LLC a Delaware limited liability company.

Kirby S. Black, Ph.D., James J. Cassidy, Ph.D., Charles W. Hewitt, Ph.D., and Ryan W. Siemens are the managers and sole members of Epic BioVentures, LLC and are thus the individuals principally responsible for managing the Fund (additional members may be admitted to the General Partner at the discretion of the General Partner's management).

The managers of the Fund have more than 100 combined years of experience in venture capital, mergers and acquisitions, operations and business development in various industries including medical technology, biotechnology, pharmaceuticals, medical devices, and healthcare.

Investment Opportunities

Epic BioVentures has already identified and initiated due diligence on over 100 companies that represent exciting investment opportunities. Some examples include:

  • A cutting edge technology for transforming blockbuster drugs: This leading pharmaceutical company focuses on transforming existing blockbuster intravenous (IV) drugs into orally administered drugs, thus eliminating the cost of IV drug administration, a $34 billion annual worldwide healthcare cost. The current terms include a $6M-10M round with an exit valuation estimated at $200M. Significant interest in acquisition includes the large pharmaceutical that currently has this drug as an IV product.
  • This company is seeking to commercially introduce the first clinically effective and financially successful means for providing short term support for patients with compromised liver function as a bridge to transplantation to liver regeneration. This company is developing a bio-artificial liver using tissue engineering and addresses a major health problem in India, Hong Kong, China and the US with a market opportunity exceeding US of $10 billion.
  • This biopharmaceutical company uses new drug delivery technology with existing and new molecules to penetrate skin for treatment of cancer, psoriasis, auto-immune and other diseases; all multi-billion dollar markets. The company can attach its proprietary technology to existing generic compounds or those facing a patent expiration. This will allow a less complex regulatory approval pathway, while providing an end-product that has increased efficacy with decreased dosage concentration, frequency, and subsequent side effects compared to the original pharmaceutical. The market size is greater than $230B. Funding needs are $12.8M to implement commercial plans to launch 2 new Rx products in next two years. The FDA approval timeframe is 24-30 months and revenue timeframe is 36 months. The expected revenue is $116M with a comparable acquiring partner exit at $935M valuation within 3 years.
  • This company is specializing in the development of therapeutic solutions for disorders of women’s sexual health. Its lead product, (“a Viagra for Women”), is a novel use fixed-dose combination (FDCP) of previously FDA-approved compounds with well-known safety and toxicity profiles. The drug can be the first safe and effective pharmacological treatment approved by the FDA for Hypoactive Sexual Desire Disorder (HSDD). The worldwide market for women’s libido drugs is estimated to be in excess of $2 billion annually. The business model is based on significant near-term gains in value, lower development costs, and an exit timeframe of 2 to 4 years. We estimate an exit event at 10X to 15X ROI.